Christy L Ludlow1. 1. Laryngeal and Speech Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, 10 Center Drive MSC 1416, Bethesda, MD 20892-1416, USA. ludlowc@ninds.nih.gov
Abstract
PURPOSE OF REVIEW: Although botulinum toxin injection is the gold standard for treatment of spasmodic dysphonia, surgical approaches aimed at providing long-term symptom control have been advancing over recent years. RECENT FINDINGS: When surgical approaches provide greater long-term benefits to symptom control, they also increase the initial period of side effects of breathiness and swallowing difficulties. Recent analyses of quality-of-life questionnaires in patients undergoing regular injections of botulinum toxin demonstrate that a large proportion of patients have limited relief for relatively short periods due to early breathiness and loss-of-benefit before reinjection. SUMMARY: Most medical and surgical approaches to the treatment of spasmodic dysphonia have been aimed at denervation of the laryngeal muscles to block symptom expression in the voice, and have both adverse effects as well as treatment benefits. Research is needed to identify the central neuropathophysiology responsible for the laryngeal muscle spasms in order target treatment towards the central neurological abnormality responsible for producing symptoms.
PURPOSE OF REVIEW: Although botulinum toxin injection is the gold standard for treatment of spasmodic dysphonia, surgical approaches aimed at providing long-term symptom control have been advancing over recent years. RECENT FINDINGS: When surgical approaches provide greater long-term benefits to symptom control, they also increase the initial period of side effects of breathiness and swallowing difficulties. Recent analyses of quality-of-life questionnaires in patients undergoing regular injections of botulinum toxin demonstrate that a large proportion of patients have limited relief for relatively short periods due to early breathiness and loss-of-benefit before reinjection. SUMMARY: Most medical and surgical approaches to the treatment of spasmodic dysphonia have been aimed at denervation of the laryngeal muscles to block symptom expression in the voice, and have both adverse effects as well as treatment benefits. Research is needed to identify the central neuropathophysiology responsible for the laryngeal muscle spasms in order target treatment towards the central neurological abnormality responsible for producing symptoms.
Authors: Hakan Birkent; Nicole Maronian; Patricia Waugh; Albert L Merati; David Perkel; Allen D Hillel Journal: Otolaryngol Head Neck Surg Date: 2009-01 Impact factor: 3.497
Authors: Priyesh N Patel; Edmond K Kabagambe; Jennifer C Starkweather; Matthew Keller; Vahram Gamsarian; Jane Lee; Vishnutheert Kulkarni; C Gaelyn Garrett; David O Francis Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-04-01 Impact factor: 6.223
Authors: Jennifer M Vojtech; Roxanne K Segina; Daniel P Buckley; Katharine R Kolin; Monique C Tardif; J Pieter Noordzij; Cara E Stepp Journal: J Acoust Soc Am Date: 2019-11 Impact factor: 1.840
Authors: Victoria S McKenna; Elizabeth S Heller Murray; Yu-An S Lien; Cara E Stepp Journal: J Speech Lang Hear Res Date: 2016-12-01 Impact factor: 2.297
Authors: H A Jinnah; Alfredo Berardelli; Cynthia Comella; Giovanni Defazio; Mahlon R Delong; Stewart Factor; Wendy R Galpern; Mark Hallett; Christy L Ludlow; Joel S Perlmutter; Ami R Rosen Journal: Mov Disord Date: 2013-06-15 Impact factor: 10.338